Updated: Aug 23, 2023
The challenges of living with Tourette syndrome and its involuntary motor and vocal tics are met with newfound hope and relief. A groundbreaking study conducted by Australian researchers, supported by HCPA’s assistance to various cannabis research businesses, has illuminated the extraordinary potential of medicinal cannabis in alleviating the debilitating effects of Tourette syndrome. Published in the prestigious New England Journal of Medicine: Evidence, this research offers hope for individuals grappling with this neurological disorder, showcasing statistically and clinically significant reductions in tics within six weeks. With the potential to redefine the quality of life for those affected, this study ushers in new possibilities for treatment.
At the forefront of this milestone are neuropsychiatrist Dr Philip Mosley, a research fellow at the Wesley Research Institute and QIMR Berghofer Medical Research Institute, who spearheaded a rigorous clinical trial. Encompassing 22 adult patients with severe Tourette syndrome, the double-masked study involved administering medicinal cannabis oil and a placebo over six weeks. The results were nothing short of remarkable.
Prescribing medicinal cannabis is a nuanced and sometimes contentious practice. HCPA’s involvement in aiding prescribers to access medicinal cannabis reflects this complexity. The study reveals the prescription of flower-based cannabis products containing THC, primarily for anxiety and mainly for males aged 31 or younger. HCPA’s expertise is essential in navigating the intricate regulations and protocols surrounding medicinal cannabis research and prescription.
Medicinal cannabis, a fusion of THC (tetrahydrocannabinol) and CBD (cannabidiol), leverages the synergistic potential of these compounds for promising outcomes. THC, the psychoactive component, and CBD, a non-psychoactive compound, combine therapeutically to establish a delicate equilibrium. The study underscores the well-tolerated nature of carefully dosed oral THC in young patients, resulting in substantial tic reduction and renewed hope.
Transformation in Patients’ Lives:
For individuals like Chris Wright, whose life has been marked by severe and painful tics since childhood, the impact has been transformative. Integrating medicinal cannabis into his treatment regimen led to a remarkable 50% decrease in tics, offering relief and empowerment. Once-daunting tasks became manageable, exemplifying the treatment’s transformative power. With Tourette syndrome affecting approximately 1% of the population, medicinal cannabis emerges as a formidable ally.
The study’s benefits extended beyond tic reduction, encompassing associated symptoms such as obsessive-compulsive disorder and anxiety. This holistic approach enhances overall well-being, creating a positive ripple effect that resonates with individuals and their families.
With the weight of a neurological disorder affecting daily life, medicinal cannabis offers hope for those seeking effective treatment. This groundbreaking study signifies a turning point in pursuing alternative therapies targeting the core of Tourette syndrome. Through its interaction with specific brain receptors, medicinal cannabis is a compelling solution for managing involuntary movements and vocalisations.
As this groundbreaking research evolves, medicinal cannabis emerges as a promise for patients and healthcare providers. Exploring its potential extends beyond Tourette syndrome, captivating the medical community’s interest in uncovering the full spectrum of benefits. With meticulous dosing and thoughtful administration, this revolutionary treatment stands poised to redefine the landscape of neurological disorder management.
Unveiling a Brighter Future:
The breakthrough study conducted by Australian researchers illuminates a new chapter of hope for individuals living with Tourette syndrome. The transformative power of medicinal cannabis, uniting THC and CBD, presents a life-altering treatment option that significantly reduces tics and enhances overall well-being. As we delve deeper into the therapeutic capacities of medicinal cannabis, the path to improved lives and advanced treatments gleams ever brighter.
HCPA is an all-in-one solution for Medicinal Cannabis providers, supporting them with registration, growth and consulting. Contact us now at here or call 03 9084 7472 to learn how we can help you succeed.
SOURCES | The University of Sydney ‘Medicinal cannabis is a ‘life-changing treatment’ for people with Tourette syndrome’ |
